Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil T Parkin

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Journal of Virology|April 29, 2005
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1Javier Martinez-Picado, Terri Wrin, Simon D W Frost, et al.
Journal of Virological Methods|July 30, 2013
Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravirThomas P Young, Laura A Napolitano, Agnes C Paquet, et al.
Journal of Virology|November 21, 2008
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudineRoger Paredes, Manish Sagar, Vincent C Marconi, et al.
Journal of Virology|February 23, 2007
Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding regionCristina Villena, Julia G Prado, Maria Carmen Puertas, et al.
The Journal of Infectious Diseases|December 7, 2019
Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical ImpactHerbert A Mbunkah, Silvia Bertagnolio, Raph L Hamers, et al.
Journal of Virology|March 21, 2008
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infectionSusan J Little, Simon D W Frost, Joseph K Wong, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2004
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavirZehava Grossman, Ellen E Paxinos, Diana Averbuch, et al.
Scientific Reports|May 29, 2024
Kinetics of SARS-CoV-2 infection biomarkers in a household transmission studyAna M Groh, Maria J G T Vehreschild, Damian Diaz, et al.
Journal of Virology|May 18, 2007
Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populationsWei Huang, Susan H Eshleman, Jonathan Toma, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2007
Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131Tomas Cihlar, Adrian S Ray, Constantine G Boojamra, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Virology|April 29, 2005
Phenotypic hypersusceptibility to multiple protease inhibitors and low replicative capacity in patients who are chronically infected with human immunodeficiency virus type 1Javier Martinez-Picado, Terri Wrin, Simon D W Frost, et al.
Journal of Virological Methods|July 30, 2013
Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravirThomas P Young, Laura A Napolitano, Agnes C Paquet, et al.
Journal of Virology|November 21, 2008
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudineRoger Paredes, Manish Sagar, Vincent C Marconi, et al.
Journal of Virology|February 23, 2007
Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding regionCristina Villena, Julia G Prado, Maria Carmen Puertas, et al.
The Journal of Infectious Diseases|December 7, 2019
Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical ImpactHerbert A Mbunkah, Silvia Bertagnolio, Raph L Hamers, et al.
Journal of Virology|March 21, 2008
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infectionSusan J Little, Simon D W Frost, Joseph K Wong, et al.
Antimicrobial Agents and Chemotherapy|May 25, 2004
Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavirZehava Grossman, Ellen E Paxinos, Diana Averbuch, et al.
Scientific Reports|May 29, 2024
Kinetics of SARS-CoV-2 infection biomarkers in a household transmission studyAna M Groh, Maria J G T Vehreschild, Damian Diaz, et al.
Journal of Virology|May 18, 2007
Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populationsWei Huang, Susan H Eshleman, Jonathan Toma, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2007
Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131Tomas Cihlar, Adrian S Ray, Constantine G Boojamra, et al.
Pageof 4